185 related articles for article (PubMed ID: 38649957)
21. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
22. A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia.
Gu W; Liu T; Fan D; Zhang J; Xia Y; Meng F; Xu Y; Cornelissen JJLM; Liu Z; Zhong Z
J Control Release; 2021 Jan; 329():706-716. PubMed ID: 33031878
[TBL] [Abstract][Full Text] [Related]
23. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
[TBL] [Abstract][Full Text] [Related]
24. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
25. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition.
Subramanian C; Grogan PT; Wang T; Bazzill J; Zuo A; White PT; Kalidindi A; Kuszynski D; Wang G; Blagg BSJ; Cohen MS
Mol Oncol; 2020 Sep; 14(9):2058-2068. PubMed ID: 32255264
[TBL] [Abstract][Full Text] [Related]
26. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
27. Retro-inverso d-peptide-modified hyaluronic acid/bioreducible hyperbranched poly(amido amine)/pDNA core-shell ternary nanoparticles for the dual-targeted delivery of short hairpin RNA-encoding plasmids.
Gu J; Chen X; Fang X; Sha X
Acta Biomater; 2017 Jul; 57():156-169. PubMed ID: 28442415
[TBL] [Abstract][Full Text] [Related]
28. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
Spiegelberg D; Mortensen AC; Selvaraju RK; Eriksson O; Stenerlöw B; Nestor M
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):974-982. PubMed ID: 26627081
[TBL] [Abstract][Full Text] [Related]
30. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
31. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery.
Wang H; Wu J; Williams GR; Fan Q; Niu S; Wu J; Xie X; Zhu LM
J Nanobiotechnology; 2019 May; 17(1):60. PubMed ID: 31084622
[TBL] [Abstract][Full Text] [Related]
32. Dually Active Targeting Nanomedicines Based on a Direct Conjugate of Two Purely Natural Ligands for Potent Chemotherapy of Ovarian Tumors.
Yan Y; Dong Y; Yue S; Qiu X; Sun H; Zhong Z
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46548-46557. PubMed ID: 31763810
[TBL] [Abstract][Full Text] [Related]
33. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
[TBL] [Abstract][Full Text] [Related]
35. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
36. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer.
Yalikong A; Li XQ; Zhou PH; Qi ZP; Li B; Cai SL; Zhong YS
Int J Nanomedicine; 2021; 16():2323-2335. PubMed ID: 33776436
[TBL] [Abstract][Full Text] [Related]
37. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.
Piotrowicz RS; Damaj BB; Hachicha M; Incardona F; Howell SB; Finlayson M
Mol Cancer Ther; 2011 Nov; 10(11):2072-82. PubMed ID: 21885863
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.
Lu C; Liu D; Jin J; Deokar H; Zhang Y; Buolamwini JK; Yu X; Yan C; Chen X
Biochem Pharmacol; 2013 May; 85(9):1246-56. PubMed ID: 23415900
[TBL] [Abstract][Full Text] [Related]
39. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
40. Nonsteroidal Anti-inflammatory Drugs Sensitize CD44-Overexpressing Cancer Cells to Hsp90 Inhibitor Through Autophagy Activation.
Moon HJ; Park SY; Lee SH; Kang CD; Kim SH
Oncol Res; 2019 Jul; 27(7):835-847. PubMed ID: 30982499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
